Handbook of Medical Hallucinogens
69,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 2-4 Wochen
  • Broschiertes Buch

This unique volume focuses on neurocognitive aspects of depression and their implications for assessment, evaluation, clinical management, and research. Experts in the field explore the impact of depression on executive function, learning and memory, working memory, and other critical capacities, and present cutting-edge assessment tools. The neurocognitive effects of antidepressant treatments are reviewed, from psychotropic medications and evidence-based psychotherapies to neuromodulation technologies. Practical aspects of working with adults across the lifespan with depression are addressed,…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This unique volume focuses on neurocognitive aspects of depression and their implications for assessment, evaluation, clinical management, and research. Experts in the field explore the impact of depression on executive function, learning and memory, working memory, and other critical capacities, and present cutting-edge assessment tools. The neurocognitive effects of antidepressant treatments are reviewed, from psychotropic medications and evidence-based psychotherapies to neuromodulation technologies. Practical aspects of working with adults across the lifespan with depression are addressed, including ways to strengthen treatment engagement and to incorporate cultural considerations.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Charles S. Grob, MD, is Professor of Psychiatry and Pediatrics at the David Geffen School of Medicine at the University of California, Los Angeles, and Director of the Division of Child and Adolescent Psychiatry at Harbor-UCLA Medical Center. He previously held faculty positions at the Johns Hopkins University and the University of California, Irvine. Dr. Grob has conducted approved clinical research with psychedelics since the early 1990s and has published numerous articles on psychedelics in the medical and psychiatric literatures, as well as several books. He is a founding board member of the Heffter Research Institute. Jim Grigsby, PhD, is Professor in the Department of Psychology, and in the Division of Health Care Policy and Research of the Department of Medicine, at the University of Colorado Denver. His research and over 250 publications have focused on neuropsychology, cognitive neuroscience, telemedicine, and other areas of health services research. His work in neuroscience includes extensive research on executive functioning and on the clinical phenotypes of fragile x-associated tremor/ataxia syndrome (FXTAS), of which he was a co-discoverer. Dr. Grigsby's current research interests include the the therapeutic use and mechanisms of psilocybin and MDMA.